Health
Medicare can now cover Eli Lilly’s Zepbound for sleep apnea, CMS says
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Medicare drug plans can now cover Eli Lilly‘s blockbuster obesity drug Zepbound for obstructive sleep apnea, CNBC confirmed on Wednesday. That opens the door for broader access to Zepbound, which is […]
Read More
Eli Lilly’s lead in the obesity race has grown. Its recent stock performance says otherwise
Eli Lilly investors have received some really good news in recent months with a notable exception of how the stock has performed. Shares of Eli Lilly entered Wednesday’s session off nearly 9% since the Oct. 30 close, the day that the drugmaker’s messy third-quarter earnings report sent the stock down 6%. Zoom out further to […]
Read More
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, August 29, 2020. Andrew Kelly | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The U.S. Food and […]
Read More
Private equity reduces patient care while enriching investors, Senate report finds
A year-long bipartisan Congressional investigation into two private equity-backed U.S. hospital systems found that patient care deteriorated at both operations as their private equity owners reaped significant payouts on their investments in the systems. The findings reinforced academic research showing how private equity healthcare investments harm patients while enriching investors. The investigation was helmed by two senators […]
Read More
J&J says its lung cancer drug combination keeps people alive longer
Niels Wenstedt | Getty Images Johnson & Johnson on Tuesday said its lung cancer regimen keeps people alive for at least a year longer than AstraZeneca‘s Tagrisso, the go-to drug for a certain type of lung cancer. J&J in a statement said its drugs – Rybrevant and Lazcluze – showed a statistically significant and clinically […]
Read More
Hims & Hers donates $1 million to Trump’s inauguration fund
Hims & Hers Health has donated $1 million to President-elect Donald Trump’s inauguration fund, CNBC confirmed Tuesday. The company, which offers a range of direct-to-consumer treatments for conditions like weight loss, erectile dysfunction and hair loss, is the latest in a string of tech companies that have tried to curry favor with the incoming administration. […]
Read More
U.S. records its first human bird flu death
Test tubes are seen labelled “Bird Flu” words in this illustration taken, June 10, 2024. Dado Ruvic | Reuters The U.S. has recorded its first human death from bird flu, a grim milestone that comes as at least 66 cases have been recorded in the country. The patient, who was over 65 and had underlying medical […]
Read More
U.S. surgeon general calls for cancer risk warnings on alcohol labels
A customer drinks a glass of beer at the Saxton Pub in Austin, Texas, April 5, 2023. Brandon Bell | Getty Images The U.S. surgeon general issued a new advisory warning Friday about the link between alcohol consumption and increased cancer risk, and pushed for policy changes to help reduce the number of alcohol-related cancers. […]
Read More
These innovative biotech stocks have a good chance of breaking out in 2025
Trends may be shifting in favor of biotech stocks in 2025 after several years of poor performance, but it would still be wise to place your bets carefully on some of the most innovative names. “We’re still optimistic on the outlook for biotech,” said Stacey Sears, senior vice president and portfolio manager at Emerald Advisors, […]
Read More
Danaher had a disappointing 2024. Its path to success next year goes through Wall Street
Life sciences firm Danaher has certainly not been an easy stock to own this year. A wave of startups going public on Wall Street would go a long ways toward changing that. Year-to-date performance: down 0.1% Forward price-to-earnings multiple: 27.8 versus a five-year average of 28.8 Our rating: Buy-equivalent 1 Our price target: $305 a […]
Read More